Skip to main content

Table 1 Demographic and clinical features of the participants

From: Development and external validation of a nomogram for neurosyphilis diagnosis among non-HIV patients: a cross-sectional study

Diagnosis Development Cohort Validation Cohort
Not or non-reactive NS Reactive NS P value Not or non-reactive NS Reactive NS P value
N 44 104   40 27  
Sex, n (%)    0·219    0·432
 Male 33 (75·0) 87 (83·7)   26 (65·0) 20 (74·1)  
 Female 11 (25·0) 17 (16·3)   14 (35·0) 7 (25·9)  
Age, years, mean (SD) 46·4 (13·7) 47·3 (11·8) 0·694 48·75 (13·40) 52·96 (16·32) 0·252
 ≥45 22 (50·0) 62 (59·6) 0·19    
 < 45 22 (50·0) 42 (40·4)     
 Height, cm, mean (SD) 164·3 (7·8) 166·5 (7·7) 0·208 165·50 (8·46) 166·63 (7·98) 0·585
 Weight, kg, mean (SD) 61·4 (9·6) 62·9 (11·4) 0·542 71·13 (20·89) 68·92 (12·59) 0·642
Education level, n (%)    0·110    0·197
 High school or beyond 19 (44·2) 30 (30·3)   13 (32·5) 13 (48·1)  
 Beyond high school 24 (55·8) 69 (69·7)   27 (67·5) 14 (51·9)  
Address, n (%)    0·088    0·202
 City 24 (55·8) 33 (33·0)   9 (22·5) 5 (18·5)  
 Urban-rural fringe area 5 (11·6) 14 (14·0)   6 (15·0) 5 (18·5)  
 Village and town 14 (32·6) 47 (47·0)   18 (45·0) 17 (63·0)  
 Other province of China 0 (0·0) 4 (4·0)   6 (15·0) 0 (0·0)  
 Aboard 0 (0·0) 2 (2·0)   1 (2·5) 0 (0·0)  
 Treatment before, n (%) 15 (43·9) 28 (27·7) 0·207 22 (55·0) 12 (44·4) 0·347
Clinical symptoms, n (%)
 No symptom 6 (13·6) 8 (7·7) 0·259 5 (12·5) 3 (11·1) 0·863
 Psychiatric behaviour disorders 9 (20·5) 52 (50·0) < 0·001 8 (20·0) 7 (25·9) 0·568
 Memory change 9 (20·5) 40 (38·5) 0·033 7 (17·5) 5 (18·5) 0·915
 Sleep difficulty 5 (11·4) 23 (22·1) 0·127 1 (2·5) 1 (3·7) 0·776
 Photophobia 6 (13·6) 8 (7·7) 0·259 2 (5·0) 1 (3·7) 0·801
 Blurred Version 4 (9·1) 6 (5·8) 0·462 3 (7·5) 1 (3·7) 0·520
 TP CLIA, mean (SD) 57·3 (42·0) 93·3 (49·9) 0·002
 1 < X < 100, n (%) 7 (16·3) 1 (1·0)   24 (60·0) 7 (25·9)  
 X > 100, n (%) 36 (83·7) 99 (99·0)   16 (40·0) 20 (74·1)  
 Creatine kinase, mean (SD), U/L 106·5 (137·3) 196·5 (373·0) 0·132 63·3 (15·1)
 Elevated CK, n (%) 2 (4·8) 20 (20·6) 0·019 0 (0)
Serum TRUST, n (%)    < 0·001    0·008
 Negative 9 (22·5) 3 (3·0)   15 (37·5) 1 (4·0)  
 1 14 (35·0) 9 (9·0)   19 (47·5) 11 (44·0)  
 8 5 (12·5) 7 (7·0)   4 (10·0) 5 (20·0)  
 16 6 (15·0) 18 (18·0)   1 (2·5) 3 (12·0)  
 32 4 (10·0) 30 (30·0)   0 (0·0) 1 (4·0)  
  ≥ 64 2 (5·0) 33(33·0)   1 (2·5) 4 (16·0)  
Serum TPPA > 1:320, n (%) 36 (81·8) 96 (92·3) 0·060 35 (87·5) 25 (96·2) 0·130
  1. Note: SD Standard deviation, Q Quartile; Neurosyphilis, NS; Elevated creatine kinase (CK) male ≥308, female ≥192 U/L; TP CLIA Treponema pallidum chemiluminescence assay; TRUST, Toluidine red unheated serum test, TPPA Treponema pallidum particle agglutination assay, IgG Immunoglobulin. Data with normal distribution are described using mean (SD)